|Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Elan is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases, and in realizing the potential of its scientific discoveries and drug delivery technologies. The Company has two business units: BioNeurology, focused primarily on neurodegenerative diseases, and Elan Drug Technologies (EDT), a drug delivery business. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. On September 17, 2009, Janssen Alzheimer Immunotherapy (Janssen AI), a newly formed subsidiary of Johnson & Johnson, completed the acquisition of substantially all of its assets and rights related to the Alzheimer's Immunotherapy Program (AIP).